Multi-Modal Nanoprobe Detects Atherosclerotic Plaques
Summary
The Sixth Medical Center of Chinese PLA General Hospital filed US Patent Application 19336412 on September 22, 2025, for a multi-modal molecular imaging nanoprobe designated Fe3O4-A12-Cy7. The probe combines fluorescence imaging (FLI), magnetic particle imaging (MPI), and computed tomography angiography (CTA) for early detection and dynamic monitoring of atherosclerotic plaques. Named inventors include Yundai Chen, Mingrui Ma, Yingqian Zhang, Suhui Zhang, Wei Tong, Rundou Chen, Hao Zhou, Zhongxuan Li, and Ziqian Wang.
“The multi-modal molecular imaging nanoprobe for early warning and dynamic monitoring of atherosclerotic plaques is Fe3O4-A12-Cy7.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
The patent application discloses a multi-modal molecular imaging nanoprobe (Fe3O4-A12-Cy7) combining fluorescence imaging, magnetic particle imaging, and computed tomography angiography for early warning and dynamic monitoring of atherosclerotic plaques. The probe utilizes protein A12, a single-domain antibody targeting PlexinD1, to achieve specific binding and imaging optimization. Healthcare institutions and medical device manufacturers engaged in cardiovascular diagnostic imaging should monitor this development for potential competitive implications in diagnostic probe technology.
The filing represents an early-stage intellectual property claim and does not currently impose regulatory obligations on third parties. Entities developing similar multi-modal imaging technologies or cardiovascular diagnostic probes may wish to review the published claims for freedom-to-operate considerations once the application advances toward examination.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MULTI-MODAL MOLECULAR IMAGING NANOPROBE FOR EARLY WARNING AND DYNAMIC MONITORING OF ATHEROSCLEROTIC PLAQUES AND USE THEREOF
Application US20260108636A1 Kind: A1 Apr 23, 2026
Assignee
THE SIXTH MEDICAL CENTER OF CHINESE PLA GENERAL HOSPITAL
Inventors
Yundai CHEN, Mingrui MA, Yingqian ZHANG, Suhui ZHANG, Wei TONG, Rundou CHEN, Hao ZHOU, Zhongxuan LI, Ziqian WANG
Abstract
The present invention belongs to the technical field of fluorescence detection, and specifically relates to a multi-modal molecular imaging nanoprobe for early warning and dynamic monitoring of atherosclerotic plaques and the use thereof. The multi-modal molecular imaging nanoprobe for early warning and dynamic monitoring of atherosclerotic plaques is Fe3O4-A12-Cy7. The probe of the present invention is Fe3O4-A12-Cy7, wherein protein A12 is a single-domain antibody that can specifically bind to PlexinD1, that is, probe Fe3O4-A12-Cy7 can specifically bind to PlexinD1, thus achieving the optimization of the target. According to the present invention, FLI/MPI/CTA is fused to form multi-modal imaging. The multi-modal imaging has the advantages of a high sensitivity and a high spatial resolution, can realize early warning and dynamic monitoring of atherosclerotic plaques, and can also visually reflect 3D stereoscopic imaging, thereby providing theoretical support and technical support for basic research.
CPC Classifications
A61K 49/1866 A61K 49/0032 A61K 49/0058 A61K 49/16 A61P 9/10
Filing Date
2025-09-22
Application No.
19336412
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.